IFN-CSP inhibiting hepatitis b virus in hepg2.2.15 cells involves JAK-STAT signal pathway

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Lu, Xuemei ^a,b   Wang, Jie ^a,b   Jin, Xiaobao ^a,b   Huang, Yanting ^a,b   Zeng, Wenting ^a,b   Zhu, Jiayong ^a,b  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b Guangzhou Higher Education Mega Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; 2',5' OLIGOADENYLATE SYNTHETASE 1; ALPHA2B INTERFERON PLASMODIUM REGION I PEPTIDE FUSION; CORE PROTEIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON REGULATORY FACTOR 9; JANUS KINASE; RECOMBINANT ALPHA2B INTERFERON; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA; ALPHA INTERFERON; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; HYBRID PROTEIN; IFNA2 PROTEIN, HUMAN; PROTOZOAL PROTEIN; STAT1 PROTEIN, HUMAN; STAT2 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; DNA REPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B VIRUS; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; VIRUS INHIBITION; WESTERN BLOTTING; HEPATITIS B; METABOLISM; PATHOLOGY; PHYSIOLOGY; PLASMODIUM; SIGNAL TRANSDUCTION;

ESCHERICHIA COLI; HEPATITIS B VIRUS;

HEP G2 CELLS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; INTERFERON-ALPHA; JANUS KINASES; PLASMODIUM; PROTOZOAN PROTEINS; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR;

EID: 84926482971     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/959684     Document Type: Article

References (25)

1. G.-F. Wang, L.-P. Shi, Y.-D. Ren et al., "Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro," Antiviral Research, Vol. 83, no. 2, pp. 186-190, 2009.
2. W. S. Ayoub and E. B. Keeffe, "Review article: current antiviral therapy of chronic hepatitis B," Alimentary Pharmacology and Therapeutics, Vol. 34, no. 10, pp. 1145-1158, 2011.
3. M.-F. Yuen and C.-L. Lai, "Hepatitis B in 2014: HBV research moves forward - receptors and reactivation," Nature Reviews Gastroenterology & Hepatology, Vol. 12, no. 2, pp. 70-72, 2014.
4. B. Liao, F. Zhang, S. Lin et al., "Epidemiological, clinical and histological characteristics of HBV/HDV co-infection: a retrospective cross-sectional study in Guangdong, China," PLoS ONE, Vol. 9, no. 12, Article ID e115888, 2014.
5. J. M. Fan, Q. Zhang, J. Xu et al., "Inhibition on Hepatitis B virus in vitro of recombinant MAP30 from bitter melon," Molecular Biology Reports, Vol. 36, no. 2, pp. 381-388, 2009.
6. H. G. Woo, S. S. Kim, H. Cho et al., "Profiling of exome mutations associated with progression of HBV-related Hepatocellular carcinoma," PLoS ONE, Vol. 9, no. 12, Article ID e115152, 2014.
7. K. Bandurska, I. Król, and M. Myga-Nowak, "Interferons: between structure and function," Postępy Higieny i Medycyny Dóswiadczalnej, Vol. 68, pp. 428-440, 2014.
8. H. Cho and B. L. Kelsall, "The role of type I interferons in intestinal infection, homeostasis, and inflammation," Immunological Reviews, Vol. 260, no. 1, pp. 145-167, 2014.
9. H. Cheon, E. C. Borden, and G. R. Stark, "Interferons and their stimulated genes in the tumor microenvironment," Seminars in Oncology, Vol. 41, no. 2, pp. 156-173, 2014.
10. L. Belloni, L. Allweiss, F. Guerrieri et al., "IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome," The Journal of Clinical Investigation, Vol. 122, no. 2, pp. 529-537, 2012.
11. F.-C. Lin and H. A. Young, "Interferons: success in anti-viral immunotherapy," Cytokine & Growth Factor Reviews, Vol. 25, no. 4, pp. 369-376, 2014.
12. Y. Suginoshita, Y. Tabata, F. Moriyasu, Y. Ikada, and T. Chiba, "Liver targeting of interferon-beta with a liver-affinity polysaccharide based on metal coordination in mice," The Journal of Pharmacology and Experimental Therapeutics, Vol. 298, no. 2, pp. 805-811, 2001.
13. K. J. Longmuir, R. T. Robertson, S. M. Haynes, J. L. Baratta, and A. J. Waring, "Effective targeting of liposomes to liver and hepatocytes in vivo by incorporation of a Plasmodium amino acid sequence," Pharmaceutical Research, Vol. 23, no. 4, pp. 759-769, 2006.
14. K. J. Longmuir, S. M. Haynes, J. L. Baratta, N. Kasabwalla, and R. T. Robertson, "Liposomal delivery of doxorubicin to hepatocytes in vivo by targeting heparan sulfate," International Journal of Pharmaceutics, Vol. 382, no. 1-2, pp. 222-233, 2009.
15. X. Lu, X. Jin, Y. Huang et al., "Construction of a novel livertargeting fusion interferon by incorporation of a Plasmodium region I-plus peptide," BioMed Research International, Vol. 2014, Article ID 261631, 8 pages, 2014.
16. L. Zheng, Q. Wang, X. Yang et al., "Antiviral activity of FNC, 2'-deoxy-2'-beta-fluoro-4'-azidocytidine, against human and duck HBV replication," Antiviral Therapy, Vol. 17, no. 4, pp. 679-687, 2012.
17. X. Bingfa, F. Qinglin, H. Hui, W. Canjun, W. Wei, and S. Lihua, "Anti-hepatitis B virus activity and mechanisms of recombinant human serum albumin-interferon-alpha-2b fusion protein in vitro and in vivo," Pharmacology, Vol. 83, no. 6, pp. 323-332, 2009.
18. X.-M. Lu, X.-B. Jin, J.-Y. Zhu et al., "Expression of the antimicrobial peptide cecropin fused with human lysozyme in Escherichia coli," Applied Microbiology and Biotechnology, Vol. 87, no. 6, pp. 2169-2176, 2010.
19. Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology, "JSH guidelines for the management of hepatitis B virus infection," Hepatology Research, Vol. 44, supplement 1, pp. 1-58, 2014.
20. S. Z. Hirschman, P. Price, E. Garfinkel, J. Christman, and G. Acs, "Expression of cloned hepatitis B virus DNA in human cell cultures," Proceedings of the National Academy of Sciences of the United States of America, Vol. 77, no. 9, pp. 5507-5511, 1980.
21. M. A. Sells, M.-L. Chen, and G. Acs, "Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA," Proceedings of the National Academy of Sciences of the United States of America, Vol. 84, no. 4, pp. 1005-1009, 1987.
22. W.-S. Xu, K.-K. Zhao, X.-H. Miao et al., "Effect of oxymatrine on the replication cycle of hepatitis B virus in vitro," World Journal of Gastroenterology, Vol. 16, no. 16, pp. 2028-2037, 2010.
23. S.-H. Cai, F.-F. Lv, Y.-H. Zhang, Y.-G. Jiang, and J. Peng, "Dynamic comparison between Daan real-time PCR and Cobas TaqMan for quantification of HBV DNA levels in patients with CHB," BMC Infectious Diseases, Vol. 14, no. 1, article 85, 2014.
24. X. Lu, X. Jin, J. Wang, F. Chu, and J. Zhu, "Antihepatitis B virus activity of a protein-enriched fraction from housefly (Musca domestica) in a stable HBV-producing cell line," The Scientific World Journal, Vol. 2014, Article ID 389560, 6 pages, 2014.
25. Q. Zhang, Y. Wang, L. Wei et al., "Role of ISGF3 in modulating the anti-hepatitis B virus activity of interferon-alpha in vitro," Journal of Gastroenterology and Hepatology, Vol. 23, no. 11, pp. 1747-1761, 2008.